Evidence map›Paper›PMID 42129099›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Antibody Humanization.

Tim D Jones

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Tim D JonesBabraham, Cambridge, UK. drtdjones@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody humanization is the process by which animal species' antibodies (usually murine) are engineered to more closely resemble human antibodies so that they are less likely to elicit anti-drug antibody responses when used clinically. The process involves selection of human antibody acceptor templates, followed by the identification of amino acids from the murine sequence that should be retained in the humanized sequence in order to preserve antigen binding; these amino acids comprise CDR residues plus additional framework resides important for maintaining the overall structure of the CDRs. Further consideration is also given to the physicochemical characteristics of the antibody and how these can be optimized during the humanization process.

Indexed as

Antibodies, Monoclonal, HumanizedProtein EngineeringAnimalsComplementarity Determining RegionsHumansMiceAntibodies, Monoclonal, HumanizedComplementarity Determining RegionsAcceptorADAAntibodyCDRDonorFrameworkGraftingHumanisation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.